Jorgensen, R., Kubale, V., Vrecl, M., Schwartz, T
To account for the pronounced heterogeneity of the preclinical evidence base, specific inclusion criteria for preclinical studies were defined as follows: (1) Model Type: utilization of established in vivo models (e.g., transgenic AD models like APP/PS1 or 3xTg-AD, neurotoxin-induced PD models, middle cerebral artery occlusion for ischemia, or high-fat diet for metabolic dysfunction) or relevant in vitro neuronal/glial cell lines
Secomandi, L., Borghesan, M., Velarde, M
Matsuo T, Yamada T, Iida T, Mochizuki S, Yoshihara A, Akimitsu K (2022) Dietary d-allulose reduces body fat accumulation in rats with and without medium-chain triacylglycerol supplementation
Sugar-sweetened beverages, including sodas and drinks made with high-fructose corn syrup, should be eliminated
Ferroptosis of T cell in inflammation and tumour immunity